This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ken Kobayashi, MD
Committee on Clinical Pharmacology and Section of Hematology/Oncology MC 2115 University of Chicago Medical Center 5841 S Maryland Ave Chicago, IL 60637-1470

David S. Pezen, MD; Nicholas J. Vogelzang, MD; Maria Medenica, MD; Linda Janisch, RN; Mark J. Ratain, MD; Everett E. Vokes, MD; Keyoumars Soltani, MD
Chicago

Arch Dermatol. 1996;132(1):96-98.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Suramin is a promising antineoplastic agent with encouraging evidence for activity in a wide variety of tumor types, including patients with hormone-refractory metastatic prostate cancer. The most common dermatologic effect is a generalized macular skin rash, which usually fades after variable periods of time and is without further clinical consequence. Erythema multiforme,¹ toxic epidermal necrolysis, disseminated superficial actinic porokeratosis, and keratoacanthomas² have also been reported.

We have treated 90 patients in a phase I doseescalation study for patients with advanced cancer to investigate the optimal means of dosing suramin.³ Patients received hydrocortisone as hormonal replacement therapy while receiving suramin by intermittent infusion over the first 2 weeks of a 28-day treatment cycle. All patients provided written informed consent, in accord with federal and institutional guidelines.

Biopsy-proven keratoacanthomas have developed in 4% (4/90) of the patients in our trial (Table); this is similar to the 10% (2/20) incidence . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?